Neoadjuvant use of endocrine therapy in breast cancer

Breast Journal

Volumn 13, Issue 3, 2007, Pages 243-250

  Macaskill, E Jane ^a   Dixon, J Michael ^a  

^a WESTERN GENERAL HOSPITAL   (United Kingdom)

Author keywords

Aromatase inhibitors; Breast cancer; Endocrine; Neoadjuvant; Tamoxifen

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; ESTROGEN RECEPTOR; EXEMESTANE; LETROZOLE; PLACEBO; PROGESTERONE RECEPTOR; TAMOXIFEN;

ADJUVANT CHEMOTHERAPY; BREAST CANCER; BREAST SURGERY; CANCER HORMONE THERAPY; CANCER PATIENT; CANCER SURGERY; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; FOLLOW UP; HUMAN; MAMMOGRAPHY; MASTECTOMY; REVIEW; TREATMENT DURATION; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS, HORMONAL; AROMATASE INHIBITORS; BREAST NEOPLASMS; COMBINED MODALITY THERAPY; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; NEOADJUVANT THERAPY; PILOT PROJECTS; RANDOMIZED CONTROLLED TRIALS; RECEPTORS, ESTROGEN; SURVIVAL ANALYSIS; TAMOXIFEN;

EID: 34247467863     PISSN: 1075122X     EISSN: 15244741     Source Type: Journal    
DOI: 10.1111/j.1524-4741.2007.00417.x     Document Type: Review

References (33)

1. Bear HD. Indications for neoadjuvant chemotherapy for breast cancer. Semin Oncol 1998 2 (Suppl. 3 3 12.
2. Perloff M, Lesnick GJ. Chemotherapy before and after mastectomy in stage III breast cancer. Arch Surg 1982 117 : 879 81.
3. Schick P, Goodstein J, Moor J, Butler J, Senter KL. Preoperative chemotherapy followed by mastectomy for locally advanced breast cancer. J Surg Oncol 1983 22 : 278 82.
4. Semiglazov VF, Semiglazov V, Ivanov V, et al. The relative efficacy of neoadjuvant endocrine therapy vs chemotherapy in postmenopausal women with ER positive breast cancer. Proc Am Soc Clin Oncol 2004 22 (14s 519.
5. Gazet JC, Ford HT, Coombes RC, et al. Prospective randomized trial of tamoxifen vs surgery in elderly patients with breast cancer. Eur J Surg Oncol 1994 20 : 207 14.
6. Kenny FS, Robertson JFR, Ellis IO, et al. Long-term follow-up of elderly patients randomised to primary tamoxifen or wedge mastectomy as initial therapy for operable breast cancer. The Breast 1998 7 : 335 9.
7. Fentiman IS, Christiaens MR, Paridaens R, et al. Treatment of operable breast cancer in the elderly: a randomised clinical trial EORTC 10851 comparing tamoxifen alone with modified radical mastectomy. Eur J Cancer 2003 39 : 309 16.
8. Mustacchi G, Ceccherini R, Milani S, et al. Tamoxifen alone versus adjuvant tamoxifen for operable breast cancer of the elderly: long-term results of the phase III randomized controlled multicenter GRETA trial. Ann Oncol 2003 14 : 414 20.
9. Fennessy M, Bates T, MacRae K, On behalf of the Closed Trials Working Party of the Cancer Research UK Breast Cancer Trials Group. Late follow-up of a randomized trial of surgery plus tamoxifen versus tamoxifen alone in women aged over 70 years with operable breast cancer. Br J Surg 2004 91 : 699 704.
10. Bates T, Fennessy M, Riley DL, On behalf of the CRC Breast Cancer Trials Group UK. Breast cancer in the elderly: surgery improves survival. The results of a Cancer Research Campaign Trial. Eur J Cancer 2001 37 (5s 7.
11. Dixon JM, Love CDB, Bellamy COC, et al. Letrozole as primary medical therapy for locally advanced and large operable breast cancer. Breast Cancer Res Treat 2001 66 : 191 9.
12. Eiermann W, Paepke S, Appfelstaedt J, et al. Preoperative treatment of postmenopausal breast cancer patients with letrozole: a randomized double-blind multicenter study. Ann Oncol 2001 12 : 1527 32.
13. Smith I, Dowsett M, Ebbs SR, et al. Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: The immediate preoperative anastrozole, tamoxifen, or combined with tamoxifen (IMPACT) multicenter double-blind randomized trial. J Clin Oncol 2005 23 : 5108 16.
14. Cataliotti L, On behalf of the PROACT trialists. Efficacy of preoperative anastrozole compared with tamoxifen in postmenopausal women with hormone receptor positive breast cancer. Germany : Presented at 4th European Breast Cancer Conference Hamburg, 2004, 17 March 2004.
15. Smith I. Anastrozole versus tamoxifen as preoperative therapy for oestrogen receptor-positive breast cancer in postmenopausal women: Combined analysis of the IMPACT and PROACT trials. Hamburg, Germany : Presented at 4th European Breast Cancer Conference, 2004, 17 March 2004.
16. Miller WR, Dixon JM. Endocrine and clinical endpoints of exemestane as neoadjuvant therapy. Cancer Control 2002 9 (2s 9 15.
17. Semiglazov VF, Semiglazov VV, Ivanov VG, et al. Neoadjuvant endocrine therapy: exemestane vs tamoxifen in postmenopausal ER+ breast cancer patients (T1-4, N1-2, M0). Proc Am Soc Clin Oncol 2005 23 (16s Abs 530.
18. Krainick U, Astner A, Jonat W, et al. Phase II study to define safety and efficacy of exemestane as preoperative therapy for postmenopausal patients with primary breast cancer - final results of the German Neoadjuvant Aromasin Initiative (GENARI). Breast Cancer Res Treat 2003 82 (1s S55, abs 239.
19. Tubiana-Hulin M, Spyratos F, Becette V, et al. Phase II study of neo-adjuvant exemestane in postmenopausal patients with operable breast cancer. Breast Cancer Res Treat 2003 82 (1s S106, abs 443.
20. Ellis MJ, Coop A, Singh B, et al. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. J Clin Oncol 2001 19 : 3808 16.
21. Horobin JM, Preece PE, Dewar JA, Wood RAB, Cushieri A. Long-term follow-up of elderly patients with locoregional breast cancer treated with tamoxifen only. Br J Surg 1991 78 : 213 7.
22. Dixon JM, Renshaw L, Bellamy C, Stuart M, Hoctin-Boes G, Miller WR. The effects of neoadjuvant anastrozole (Arimidex) on tumor volume in postmenopausal women with breast cancer: a randomized, double-blind, single-center study. Clin Cancer Res 2000 6 : 2229 35.
23. Keen JC, Dixon JM, Miller EP, et al. The expression of KiS1 and BCL-2 and the response to primary tamoxifen therapy in elderly patients with breast cancer. Breast Cancer Res Treat 1997 44 : 123 33.
24. Miller WR, Anderson TJ, Hawkins RA, Keen J, Dixon JM. Neoadjuvant endocrine treatment: the Edinburgh experience. In : Howell A, Dowsett M, eds. Primary Medical Therapy for Breast Cancer: Clinical and Biological Aspects, Vol 4. Amsterdam : Elsevier Science B.V, 1999 : 89 99.
25. Ellis MJ, Coop A, Singh B, et al. Letrozole inhibits tumor proliferation more effectively than tamoxifen independent of HER 1/2 expression status. Ca Res 2003 63 : 6253 31.
26. Miller WR, Dixon JM, Macfarlane L, Cameron D, Anderson TJ. Pathological features of breast cancer response following neoadjuvant treatment with either letrozole or tamoxifen. Eur J Cancer 2003 39 : 462 8.
27. Howell A, On behalf of the ATAC Trialists' Group. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years adjuvant treatment for breast cancer. Lancet 2005 365 : 60 2.
28. Dowsett M, A'Hern R, Smith I, On behalf of the IMPACT Trialists. Ki67 after 2 weeks' endocrine treatment predicts relapse-free survival (RFS) in the IMPACT trial. Breast Cancer Res Treat 2005 94 (s1 abs 45.
29. Dixon JM, Jackson J, Hills M, et al. Anastrozole demonstrates clinical and biological effectiveness in oestrogen-receptor-positive positive breast cancers, irrespective of the erbB2 status. Eur J Cancer 2004a 40 : 2742 7.
30. Young O, Murray J, Renshaw L, et al. Neoadjuvant letrozole is equally effective in HER2 positive and negative breast cancers. Breast Cancer Res Treat 2004 88 (1s S36, abs 411.
31. Ellis MJ, Tao Y, Young O, et al. Estrogen-independent proliferation is present in estrogen-dependent HER2-positive primary breast cancer after neoadjuvant letrozole. J Clin Oncol 2006 24 : 3019 25.
32. Dixon JM. Neoadjuvant therapy: surgical perspectives. In : Miller WR, Ingle JN, eds. Endocrine Therapy in Breast Cancer. New York : Marcel Dekker, 2002 : 197 212.
33. Dixon JM, Renshaw L, Murray J, et al. Is there an optimal duration of neoadjuvant letrozole therapy? Breast Cancer Res Treat 2004b 88 (1s S36, abs 405.